Abstract
Non-alcoholic fatty liver diseases are the hepatic manifestation of metabolic syndrome. According to the classical pattern of NAFLD progression, de novo fatty acid synthesis has been incriminated in NAFLD progression. However, this hypothesis has been challenged by the re-evaluation of NAFLD development mechanisms together with the description of the role of lipogenic genes in NAFLD and with the recent observation that PGC-1β, a nuclear receptor/transcription factor coactivator involved in the transcriptional regulation of lipogenesis, displays protective effects against NAFLD/NASH progression. In this review, we focus on the implication of lipogenesis and triglycerides synthesis on the development of non-alcoholic fatty liver diseases and discuss the involvement of these pathways in the protective role of PGC-1β toward these hepatic manifestations.
Original language | English |
---|---|
Pages (from-to) | 3809-3822 |
Number of pages | 14 |
Journal | Cellular and Molecular Life Sciences |
Volume | 73 |
Issue number | 20 |
DOIs | |
Publication status | Accepted/In press - Aug 13 2016 |
Keywords
- Coactivator
- Lipogenesis
- Liver
- NAFLD
- NASH
- Nuclear receptor
- PGC-1
- Steatohepatitis
ASJC Scopus subject areas
- Medicine(all)
- Molecular Medicine
- Molecular Biology
- Pharmacology
- Cellular and Molecular Neuroscience
- Cell Biology